SG11202106847SA - Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions - Google Patents
Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditionsInfo
- Publication number
- SG11202106847SA SG11202106847SA SG11202106847SA SG11202106847SA SG11202106847SA SG 11202106847S A SG11202106847S A SG 11202106847SA SG 11202106847S A SG11202106847S A SG 11202106847SA SG 11202106847S A SG11202106847S A SG 11202106847SA SG 11202106847S A SG11202106847S A SG 11202106847SA
- Authority
- SG
- Singapore
- Prior art keywords
- pain
- treatment
- inflammatory conditions
- peptide analogs
- conotoxin peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/012307 WO2020142102A1 (en) | 2019-01-04 | 2019-01-04 | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106847SA true SG11202106847SA (en) | 2021-07-29 |
Family
ID=65244618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106847SA SG11202106847SA (en) | 2019-01-04 | 2019-01-04 | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3906253A1 (en) |
| JP (1) | JP2022522935A (en) |
| KR (1) | KR20210116505A (en) |
| CN (1) | CN113966339A (en) |
| AU (1) | AU2019418319A1 (en) |
| BR (1) | BR112021013302A2 (en) |
| CA (1) | CA3125383A1 (en) |
| CL (1) | CL2021001775A1 (en) |
| CO (1) | CO2021008845A2 (en) |
| CR (1) | CR20210363A (en) |
| IL (1) | IL284574A (en) |
| MX (1) | MX2021008070A (en) |
| PE (1) | PE20211734A1 (en) |
| SG (1) | SG11202106847SA (en) |
| WO (1) | WO2020142102A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230033485A (en) | 2021-09-01 | 2023-03-08 | 삼성전자주식회사 | Storage device and operating method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5558817B2 (en) * | 2006-07-18 | 2014-07-23 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | Pain treatment method and analgesic compound screening method |
| US9284358B2 (en) | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
| US20090326192A1 (en) * | 2008-04-08 | 2009-12-31 | Aileron Therapeutics, Inc. | Biologically active peptidomimetic macrocycles |
| US11014970B2 (en) | 2014-11-07 | 2021-05-25 | Kineta Chronic Pain, Llc | Modifications and uses of conotoxin peptides |
-
2019
- 2019-01-04 PE PE2021001115A patent/PE20211734A1/en unknown
- 2019-01-04 MX MX2021008070A patent/MX2021008070A/en unknown
- 2019-01-04 WO PCT/US2019/012307 patent/WO2020142102A1/en unknown
- 2019-01-04 CA CA3125383A patent/CA3125383A1/en active Pending
- 2019-01-04 CN CN201980093540.XA patent/CN113966339A/en active Pending
- 2019-01-04 KR KR1020217024613A patent/KR20210116505A/en active Search and Examination
- 2019-01-04 EP EP19702500.0A patent/EP3906253A1/en active Pending
- 2019-01-04 CR CR20210363A patent/CR20210363A/en unknown
- 2019-01-04 JP JP2021538994A patent/JP2022522935A/en active Pending
- 2019-01-04 BR BR112021013302-0A patent/BR112021013302A2/en unknown
- 2019-01-04 AU AU2019418319A patent/AU2019418319A1/en active Pending
- 2019-01-04 SG SG11202106847SA patent/SG11202106847SA/en unknown
-
2021
- 2021-07-02 CO CONC2021/0008845A patent/CO2021008845A2/en unknown
- 2021-07-02 IL IL284574A patent/IL284574A/en unknown
- 2021-07-02 CL CL2021001775A patent/CL2021001775A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3906253A1 (en) | 2021-11-10 |
| CA3125383A1 (en) | 2020-07-09 |
| WO2020142102A1 (en) | 2020-07-09 |
| CL2021001775A1 (en) | 2022-05-27 |
| MX2021008070A (en) | 2021-10-13 |
| KR20210116505A (en) | 2021-09-27 |
| CR20210363A (en) | 2021-12-10 |
| BR112021013302A2 (en) | 2021-09-14 |
| JP2022522935A (en) | 2022-04-21 |
| CO2021008845A2 (en) | 2021-10-29 |
| WO2020142102A9 (en) | 2020-11-19 |
| AU2019418319A1 (en) | 2021-07-22 |
| CN113966339A (en) | 2022-01-21 |
| PE20211734A1 (en) | 2021-09-06 |
| IL284574A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275777A (en) | Improved peptide pharmaceuticals for treatment of nash and other disorders | |
| SG11201912195TA (en) | Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| IL284414A (en) | Methods and compositions for the treatment of fabry disease | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| IL284574A (en) | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions | |
| ZA202100587B (en) | Peptide compounds and therapeutic uses of same | |
| EP4076671A4 (en) | Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same | |
| EP3765055C0 (en) | Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes | |
| IL276228A (en) | Compounds and compositions for the treatment of pain | |
| SG10201902000YA (en) | Isthmin 1 for treatment of lung inflammation | |
| GB201904374D0 (en) | Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders | |
| EP3836949A4 (en) | Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
| GB2574944B (en) | Methods and compositions for the treatment of pain and/or inflammation | |
| EP4003283C0 (en) | Treatment of inflammatory skin conditions | |
| ZA202106250B (en) | Therapeutic uses of dulaglutide | |
| GB201913312D0 (en) | Treatment of hypothyroidism and related conditions | |
| IL287529B (en) | Pharmaceutical combination comprising trazodone for the treatment of neuropathic pain | |
| GB201718856D0 (en) | Medicinal compositions for the treatment of inflammatory conditions and autoimmune diseases | |
| ZA201904326B (en) | Treatment of joint pain | |
| GB201816914D0 (en) | Treatment of inflammation | |
| GB201817343D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |